Inhibitory effects of Tripterygium wilfordii multiglycoside on benign prostatic hyperplasia in rats.
10.1016/S1875-5364(15)30035-2
- Author:
Hai-Nan SHEN
1
;
Yuan XU
1
;
Zhen-Zhou JIANG
2
,
3
;
Xin HUANG
2
,
4
;
Lu-Yong ZHANG
2
,
5
;
Tao WANG
2
,
6
Author Information
1. Jiangsu Center of Drug Screening, China Pharmaceutical University, Nanjing 210009, China.
2. Jiangsu Center of Drug Screening, China Pharmaceutical University, Nanjing 210009, China
3. Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing 210009, China.
4. Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, China.
5. Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing 210009, China. Electronic address: lyzhangchina@hotmail.com.
6. Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, China. Electronic address: wangtao1331@126.com.
- Publication Type:Journal Article
- Keywords:
Benign prostatic hyperplasia;
Dihydrotestosterone;
Multiglycoside;
Testosterone;
Tripterygium wilfordii
- MeSH:
Animals;
Disease Models, Animal;
Drugs, Chinese Herbal;
administration & dosage;
Glycosides;
administration & dosage;
Humans;
Male;
Prostate;
drug effects;
metabolism;
Prostatic Hyperplasia;
drug therapy;
metabolism;
Rats;
Testosterone;
metabolism;
Tripterygium;
chemistry
- From:
Chinese Journal of Natural Medicines (English Ed.)
2015;13(6):421-427
- CountryChina
- Language:English
-
Abstract:
The present study was designed to evaluate the inhibitory effects of Tripterygium wilfordii multiglycoside (GTW) against testosterone-induced benign prostatic hyperplasia (BPH) in rats. A total of 45 rats were randomly divided into five groups: Group I, vehicle control group (sham-operated and treated with vehicle); Group II, BPH group; Group III, BPH rats treated with finasteride at a dose of 5 mg·kg(-1); and Groups IV and V, BPH rats treated with GTW at dose levels of 10 and 20 mg·kg(-1), respectively. The drugs were administered orally once a day for 14 days. Prostate weight, prostatic index, and the testosterone and dihydrotestosterone (DHT) levels in serum and prostate, and the serum prostate specific antigen (PSA) levels were measured; prostate tissues were taken for histopathological examination; and serum biochemical analysis was also performed. The BPH rats displayed an increase in prostate weight, prostatic index with increased testosterone and DHT levels in both the serum and prostate, and increased serum PSA levels. GTW treatment at both doses resulted in significant reductions in prostate weight, prostatic index, testosterone and DHT levels in both the serum and prostate, and serum PSA levels, compared with BPH group. Histopathological examination also indicated that GTW treatment at both doses inhibited testosterone-induced prostatic hyperplasia. Serum biochemical analysis showed that the liver and renal functions were normal. In conclusion, GTW inhibited testosterone-induced prostatic hyperplasia in rats, without host toxicity, providing a basis for the development of GTW as a novel therapy for BPH.
